Given the growing evidence that RASi have a role in reducing the risk and progression of PCa, and that we identified angiotensin related signaling as enriched pathways in ERGhigh tumors, which were associated with a reduced risk of BCR compared with the ERGlow tumor group, together these results warrant further research exploring RASi in patients with T2E arrangements or differential expression of ERG and different subtypes. This evidence concerns the gene ERG and neoplasm.